Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease

This study evaluates the effect of three different bronchodilators (beta 2-adrenergic, anticholinergic and methylxanthine) alone and in randomized sequence, during an exacerbation in thirteen patients with chronic obstructive pulmonary disease. Dose-response curves were obtained for inhaled salbutamol and inhaled ipratropium bromide. The bronchodilator effect of a perfusion of aminophylline was also assessed. When a plateau of bronchodilatation was achieved with one agent, one dose of a second bronchodilator was administered to see whether additional bronchodilation could be achieved. The increments in FEV1 and FVC were similar with the three agents. The addition of a second bronchodilator did not result in significant increments in most of the patients. In at least half of the patients the doses of salbutamol and ipratropium that produced the maximal bronchodilatation were twice that currently employed.

This article has been cited by other articles:

				K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555. [Abstract] [Full Text] [PDF]

				S. Nair, E. Thomas, S. B. Pearson, and M. T. Henry A Randomized Controlled Trial To Assess the Optimal Dose and Effect of Nebulized Albuterol in Acute Exacerbations of COPD Chest, July 1, 2005; 128(1): 48 - 54. [Abstract] [Full Text] [PDF]

				R G. Barr, B. H Rowe, and C. A Camargo Jr Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials BMJ, September 20, 2003; 327(7416): 643. [Abstract] [Full Text] [PDF]

				A J White, S Gompertz, and R A Stockley Chronic obstructive pulmonary disease * 6: The aetiology of exacerbations of chronic obstructive pulmonary disease Thorax, January 1, 2003; 58(1): 73 - 80. [Abstract] [Full Text] [PDF]

				R. A. PAUWELS, A. S. BUIST, P. M. A. CALVERLEY, C. R. JENKINS, and S. S. HURD Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease . NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1256 - 1276. [Full Text]

				N. F. Voelkel and R. Tuder COPD : Exacerbation Chest, May 1, 2000; 117(5_suppl_2): 376S - 379S. [Abstract] [Full Text] [PDF]

				M. Friedman, C. W. Serby, S. S. Menjoge, J. D. Wilson, D. E. Hilleman, and T. J. Witek Jr. Pharmacoeconomic Evaluation of a Combination of Ipratropium Plus Albuterol Compared With Ipratropium Alone and Albuterol Alone in COPD Chest, March 1, 1999; 115(3): 635 - 641. [Abstract] [Full Text] [PDF]